[A case of metastatic colorectal cancer that reduced in size after re-challenging with an anti-EGFR monoclonal antibody].
A 58-year-old woman was confirmed as having multiple liver metastases after undergoing a high anterior resection for a sigmoid colon tumor. She was administered bevacizumab+FOLFOX as the first regimen and bevacizumab+FOLFIRI and S-1 and irinotecan (IRIS)therapy as the second regimen. During this treatment she also underwent hepatectomy 3 times and radiofrequency ablation once. She was administered panitumumab+irinotecan as the third regimen and, due to the presence of multiple pulmonary metastases, was subsequently considered to have had a partial response (PR). Because she subsequently developed progressive disease (PD), she received the fourth regimen as part of a clinical trial (TAS102) in another hospital. Cetuximab+irinotecan was administered as the fifth regimen after PD and the tumor was found to have reduced in size by 23%upon computed tomography (CT) 2 months later. Although stable disease (SD) was achieved, she was subsequently administered regorafenib for 8 months as a sixth regimen after the disease progressed a second time. In some cases of KRAS wild type metastatic colorectal cancer, re-challenging with an anti-epidermal growth factor receptor (EGFR) monoclonal antibody seems to be an effective strategy for reducing tumor mass.
Dept. of Surgery, Sakai City Hospital.
Mutsumi
M
Fukunaga
Ken
K
Nakata
Akihito
A
Babaya
Katsushu
K
Shimizu
Takahiko
T
Ishigaki
Takeshi
T
Ebihara
Satoshi
S
Okubo
Fumitaka
F
Kato
Kouji
K
Amano
Hiromitsu
H
Hoshino
Ryohei
R
Kawabata
Jun
J
Yamamura
Shunji
S
Kamigaki
Akihiro
A
Usui
Naoki
N
Ikeda
Tameyoshi
T
Yamamoto
Tomono
T
Kawase
Yutaka
Y
Kimura
Hiroki
H
Ohzato
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000276:immunology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008875:Middle Aged; D000077544:Panitumumab; D012811:Sigmoid Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000911:Antibodies, Monoclonal; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors